Researchers at Ohio State University have identified a molecule that can reverse damage and help restore blood flow to vessels constricted during a heart attack. The treatment involves delivering tetrahydrobiopterin directly to the vessels, which can improve outcomes for patients with acute coronary episodes.
Patients with depression have impaired heart rate variability recovery after acute coronary syndromes, but treatment with antidepressants improves this ability. Sertraline treatment also increased heart rate variability in depressed patients.
Patients with diabetes and acute coronary syndromes have a significantly higher risk of death at 30 days and one year compared to those without diabetes. The study found that diabetes increased the risk of death by nearly 80% at 30 days for patients with unstable angina/non-STEMI and 40% for those with STEMI.
A re-analysis of the data used in a controversial meta-analysis suggests that rosiglitazone's cardiovascular risks may not be as high as initially reported. The study finds that only prospective clinical trials can definitively establish the drug's safety.
Researchers identified a new player in the control of good cholesterol that circulates in the bloodstream and reduces heart attack risk. By manipulating levels of an enzyme called proprotein convertases, they were able to boost or reduce HDL-C levels, offering potential for therapies against heart disease.
The revised guidelines introduce changes to the initial diagnostic approach, recommending a non-invasive set of preliminary tests such as stress tests or echocardiograms. The new guidelines also emphasize the importance of more intense lipid and blood pressure control, as well as the use of anti-platelet therapy clopidogrel for at leas...
A study published in The American Journal of Medicine found that emergency angioplasty use has increased, but 10% of eligible patients are still going untreated for life-saving treatment after a heart attack. Patients without typical symptoms or from underrepresented groups are most likely to miss out on this critical care.
A new study found that emergency angioplasty treatment for heart attacks has increased dramatically over the last decade, with a notable decline in patients going without crucial care. However, 10% of eligible patients still do not receive this urgent treatment, highlighting gaps in care for certain subgroups.
Researchers demonstrate in rats that a periostin patch can stimulate heart cell regeneration and improve cardiac pumping ability. The treated rats showed improved ventricular remodeling, decreased scarring, and increased cardiomyocyte proliferation.
Two studies found that elevated nonfasting triglyceride levels are associated with an increased risk of heart attacks, ischemic heart disease, and death. The findings suggest that remnant lipoproteins play a dominant role in postprandial atherosclerosis, and may predict the risk of cardiovascular events in women.
A recent study published in the European Journal of Cardiovascular Nursing reveals that women who have suffered heart attacks experience higher rates of lingering depressive symptoms compared to their male counterparts. Women scored lower in physical and social functioning after one year, with 14.3% experiencing worsening depression.
A study suggests that taxing high-fat foods in the UK could prevent up to 3,000 heart attack and stroke deaths annually. This approach would increase salt intake instead of reducing it, leading to potential health issues.
A recent study by the University of Edinburgh found that South Asian Scots are more likely to suffer a heart attack than the rest of the Scottish population. The research, which linked census data to hospital discharge records, revealed an 80% higher incidence of heart attacks among South Asian women and a 45% higher incidence among men.
A new study found high levels of MPO to signal increased risk for heart disease nearly a decade before conventional risk factors set off alarms. Elevated MPO levels also indicate unstable plaque and may be used to detect vulnerable patients.
Researchers explored the use of autologous cells derived from bone marrow cells (BMC) to strengthen cardiac function and prevent heart attacks. The study found a significant reduction in clinical events, including death, heart attack, or revascularization, in patients who received BMC infusion compared to placebo.
Researchers will inject selected stem cells from patients' own bone marrow into their hearts during coronary bypass surgery. The goal is to prevent late scar formation and improve heart contraction, reducing the risk of congestive heart failure.
Research published in the European Heart Journal reveals obese and very obese patients have a lower risk of dying after treated for heart attacks compared to normal-weight patients. After three years of follow-up, obese patients had less than half the long-term mortality rate as normal BMI patients.
A multidisciplinary team approach has successfully treated acute heart attacks by expediting patients to specialized treatment centers within 90 minutes. This program evaluation demonstrates improved outcomes for ST-segment elevation myocardial infarction patients in Canada.
A study found that paying hospitals extra money for following treatment guidelines didn't improve patient outcomes. However, providing hospitals with the necessary information to improve care did lead to better results.
A study found that only 32% of adults possess minimal medical knowledge of serious health conditions, despite higher education or personal experience not providing significant improvement. This lack of awareness poses a risk to early detection and treatment outcomes, as well as public health costs and behavior.
Women who drink in moderation have a significantly lower risk of heart attack compared to abstainers, with daily drinkers experiencing the most benefits. Moderate drinking reduces heart attack risk regardless of beverage preference or pattern.
A new study has found that sleep apnea significantly increases the risk of heart attack or death over a period of four to five years. Researchers followed 1,123 patients with sleep apnea for five years and found that those with more severe symptoms were at higher risk of developing heart disease.
A study by Society for Cardiovascular Angiography and Interventions (SCAI) uses wireless technology to transmit ECGs from paramedics' smartphones to cardiologists, allowing for faster treatment of heart attacks. The system has cut the door-to-balloon time in half, improving patient care.
A study found that diabetic patients who continued long-term clopidogrel therapy had lower rates of heart attack and death compared to those who discontinued the medication, regardless of stent type. Long-term clopidogrel therapy was particularly beneficial in reducing mortality risk with bare metal stents.
A study of over 8,000 British government workers found that unfair treatment increased the risk of a heart attack or angina, with those in the highest category being 55% more likely to have serious heart disease. Women and lower-income individuals were also disproportionately affected.
Experts disagree on the criticality of a 90-minute door-to-balloon time in heart attack treatment. Dr. Eric R. Bates believes that timely balloon inflation is crucial for better outcomes, while Dr. Timothy D. Henry argues that an arbitrary deadline may be counterproductive in some cases.
Pretreatment with high-dose clopidogrel (600 mg or more) reduces the risk of cardiac death or nonfatal heart attack by 50% during hospitalization and within 30 days after PCI. The study found no increase in major or minor bleeding, regardless of dose.
Young women with heart disease often experience atypical symptoms such as jaw pain, sweating, and shortness of breath. These individuals are twice as likely to die in the hospital compared to similarly aged men, highlighting the need for prompt medical attention and increased awareness of risk factors.
A University of Kentucky study finds that doses higher than a baby aspirin may not prevent cardiovascular events and increase bleeding risk. The research suggests that using the minimum effective dose of 75-81 mg may be optimal for most patients.
A randomized trial found that angioplasty significantly reduced long-term cardiac events compared to intensive drug therapy among heart attack survivors with silent ischemia. The study followed 201 patients for an average of 10.2 years, revealing a persistent benefit of PCI.
Two studies reveal that off-label and untested use of drug-coated stents is common in US practice, associated with higher ischemic complication rates and worse short-term outcomes. The studies found that approximately half of all use of drug-eluting stents occurs in off-label or untested settings.
A common genetic variation on chromosome 9p21 is linked to a substantial increase in risk for heart attack, with individuals carrying the variation having a 1.64-fold greater risk of suffering a heart attack. The study found that approximately 21 percent of individuals of European descent carry two copies of the genetic variation.
A new international study found that patients who received modern treatments after a heart attack or severe chest pain had significantly lower death rates, stroke risks, and heart failure. The study shows improved outcomes due to increased use of guideline-based treatments such as drugs, tests, and procedures.
Recent changes in treatment guidelines for acute coronary syndromes have been associated with reductions in heart failure, stroke, and death rates. The use of pharmacological medications increased over time, while primary PCI rates rose by 37 percentage points.
Researchers found a significant decline in death rates and heart failure among patients with severe heart attacks, with reductions of 4.5% and 11%, respectively. The study also showed improvements in stroke and further heart attack risk.
A study published in JAMA found that ranolazine is safe but ineffective in reducing major cardiovascular events, such as death or heart attack, in patients with acute coronary syndromes. The medication showed a reduced risk of recurrent ischemia, but failed to improve overall cardiovascular outcomes.
The FDA has added 'black box' warnings to all prescription and over-the-counter pain relievers, despite evidence showing naproxen is safe. This decision ignores the risk differences between nonsteroidal anti-inflammatory drugs, with Voltaren carrying the highest risk of heart attack.
Researchers found HIV-infected patients had a higher incidence of heart attacks and major cardiovascular risk factors compared to noninfected patients. The study's findings indicate that HIV-infected individuals should be assessed for cardiovascular risks and that strategies to modify those risks are urgently needed.
Research shows that elderly patients (90+ years) who receive recommended treatments for acute coronary syndromes have better survival rates, but at a higher risk of bleeding complications. Guidelines must be balanced to balance survival benefits with increased bleeding risk.
Migraines in men are associated with a higher risk of cardiovascular disease and heart attacks. The study found that men who experienced migraines had an increased risk of myocardial infarctions, with an incidence rate of 10.4 per 10,000 men per year.
Researchers at Mount Sinai School of Medicine have developed a new imaging technology using multi-detector computed tomography (CT) and a novel contrast agent N1177 to detect high-risk plaque. This may help physicians diagnose a heart attack before it occurs, preventing cardiac events.
A new study found that doctors are treating patients with early symptoms of a heart attack with the same level of urgency as those with later-confirmed cases. This suggests that doctors are using alternative data sources, such as patient history and electrocardiogram results, to make treatment decisions.
A study of 119 Iowa hospitals found that rural hospitals do not have higher death rates for heart attack care, contrary to previous research. The study used a more sensitive analytic method to control for biases and found comparable patient outcomes.
Research found ibuprofen may boost the likelihood of heart problems in high-risk patients with osteoarthritis. High-dose ibuprofen was linked to a higher risk of heart attacks and strokes compared to other treatments, including lumiracoxib and naproxen.
A Phase I study at Rush University Medical Center found that adult stem cell therapy significantly improved heart, lung, and global function in heart attack patients. Patients receiving the therapy experienced a lower number of adverse events and were 75% less likely to experience arrhythmic events compared to those receiving a placebo.
A study assessed whether adding succinobucol, a novel agent with antioxidant and anti-inflammatory properties, to optimal medical therapy reduces coronary events and death. The trial achieved a 19% relative risk reduction in hard atherosclerotic clinical endpoints, including cardiovascular death, myocardial infarction, and stroke.
The COURAGE trial found that PCI reduces neither mortality nor heart attack in patients with chronic stable angina when added to optimal drug therapy. SCAI leaders emphasize the importance of discussing treatment options and goals with patients, as therapy may not be suitable for every patient.
A new five-year study published in the New England Journal of Medicine found that stable heart patients received no significant benefit from undergoing angioplasty compared to those treated with medication alone. The study showed a 19.5% rate of death, heart attack, and stroke among medication-only patients versus 20% for PCI recipients.
A study published in the Journal of Neuroscience found that multiple regions of the brain are involved in determining pain location, contradicting conventional wisdom. The research used functional magnetic resonance imaging (MRI) to identify areas of brain activity while participants evaluated the spatial location of a thermal stimulus.
A new thrombin-receptor antagonist (TRA) has shown significant reduction in serious cardiovascular events, mainly heart attacks, with no increase in bleeding risks in a high-risk patient population. The study found a 46% lowering in serious cardiovascular events, an early and strong efficacy signal for this novel antiplatelet compound.
A study published in the New England Journal of Medicine found that pairing percutaneous coronary interventions (PCI) with optimal medical therapy (OMT) is no more effective than OMT alone in preventing heart attacks and other cardiac events. The study showed similar rates of death, heart attack, or stroke between patients who received...
A Phase 1 study evaluating a novel protein kinase C inhibitor, KAI-9803, suggests potential benefit in healing time and tissue function for heart attack patients. The trial showed improved tissue perfusion and reduced infarct size at lower dose levels.
Researchers studied the outcomes of treating ST- elevation myocardial infarction with PCI alone or with distal protection, finding similar major adverse cardiac events and electrocardiographic results. However, post-procedure blood flow was improved in patients treated with distal protection.
The study found that Crestor arrested the progression of thickened carotid arteries in participants with moderately elevated cholesterol levels. The therapy also lowered low-density lipoprotein and increased high-density lipoprotein, as well as reduced triglycerides.
A study comparing drug-eluting stents (DES) and bare-metal stents (BMS) found similar rates of complications, including stent thrombosis, MI, and mortality. However, DES patients had a slightly increased risk of stent thrombosis and heart attack between 12-15 months after implantation.
A large study found that patients with established arterial disease have significantly higher cardiovascular event rates than those with multiple risk factors only. The rates increased directly with the number of symptomatic arterial disease locations, emphasizing the need for improved secondary prevention and clinical outcomes.
A national study will enroll 1,124 participants to investigate implanting a pacemaker in low-heart rate, heart-attack patients to improve survival rates and determine the frequency of low heart rates in these patients. The five-year study aims to explore the effectiveness of beta-blocker therapy for this specific patient group.
Researchers found that erectile dysfunction drugs like Viagra and Levitra can reduce heart damage after a heart attack, while nitroglycerin failed to offer similar protection. The study suggests these drugs may have potential as adjunct therapy for patients undergoing high-risk procedures or experiencing cardiac arrest.
A new clinical trial has shown that intensive treatment for periodontitis, a common inflammatory gum disease, can improve blood vessel function and reduce the risk of heart attacks and strokes. The study suggests that treating gum disease could be an important step in preventing cardiovascular disease.
A study of 24 couples found that nine reported positive changes in their lives after the experience, including increased closeness and practical adjustments. Meanwhile, ten couples felt fearful and threatened by the uncertainty of their partner's health, while five others failed to make meaningful changes.